ProfileGDS5678 / 1423513_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 60% 57% 59% 59% 58% 60% 57% 58% 63% 56% 57% 63% 58% 57% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6328160
GSM967853U87-EV human glioblastoma xenograft - Control 23.4710457
GSM967854U87-EV human glioblastoma xenograft - Control 33.5464159
GSM967855U87-EV human glioblastoma xenograft - Control 43.4789659
GSM967856U87-EV human glioblastoma xenograft - Control 53.4757658
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6843460
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5481857
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5128358
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7764963
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3783556
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.4535157
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.7340763
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.5286858
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.4622357